Mucin Glycosylating Enzymes in Head and Neck Cancers
Conditions
Mucin Glycosylating Enzyme, HNSCC
Conditions: official terms
Head and Neck Neoplasms
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Case Control, Time Perspective: Retrospective
Overall Status
Recruiting
Summary
Head and neck squamous cell carcinoma(HNSCC) is the fourth common malignancy in Taiwan. It accounts for 5.8% of all cancers and causes 2,463 deaths per year. Aberrant glycosylation is the hallmark of most human cancers, including HNSCC, and affects many cellular properties. This study is aimed at exploring the role of mucin glycosylating enzymes in HNSCC.
Detailed Description
Glycosylation is the most common post-translational modification of proteins. Aberrant glycosylation is the hallmark of most human cancers and affect many cellular properties, including cell proliferation, apoptosis, differentiation, transformation, migration and immune response.

Though widely explored in various human cancers, the role of mucin glycosylating enzymes in HNSCC has not been elucidated. Our aims is to analyze the expression patterns of mucin glycosylating enzymes in HNSCC tissues. Furthermore, we will correlate the expression levels of mucin glycosylating enzymes with clinical characteristics of HNSCC patients.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 90 Years
Minimum Age: 20 Years
Gender: Both
Criteria: Inclusion Criteria:

- Head and neck cancer patients receiving operation in National Taiwan University Hospital

Exclusion Criteria:

- Recurrence or non-operable patients
Location
National Taiwan University
Taipei, Taiwan
Status: Recruiting
Contact: Pei-Jen Lou, MD, PhD - 886-972651527 - pjlou@ntu.edu.tw
Start Date
October 2013
Completion Date
October 2016
Sponsors
National Taiwan University Hospital
Source
National Taiwan University Hospital
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page